Effects of Everolimus on Cytokines, Oxidative Stress, and Renal Histology in Ischemia-Reperfusion Injury of the Kidney

REFERENCES

• Bonventre JV, Zuk A. Ischemic acute renal failure: An inflammatory disease?. Kidney Int. 2004;66:480–485.
   PubMed Web of Science ®Google Scholar
• Lameire N, Biesen WV, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430.
   PubMed Web of Science ®Google Scholar
• Sheridan AM, Bonventre JV. Pathophysiology of ischemic acute renal failure. Contrib Nephrol. 2001;132:7–21.
   Web of Science ®Google Scholar
• Molitoris BA, Sutton TA. Endothelial injury and dysfunction: Role in the extension phase of acute renal failure. Kidney Int. 2004;66:496–499.
   PubMed Web of Science ®Google Scholar
• Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc. 2004;36(Suppl. 2):500–503.
   Google Scholar
• Tan HP, Basu A, Shapiro R. Everolimus: An update. Curr Opin Organ Transplant. 2003;8:323–326.
   Google Scholar
• Schuurman HJ, Pally G, Weckbecker G, SDZ RAD inhibits cold ischemia-induced vascular remodeling. Transplant Proc. 1999;31:1024–1025.
   PubMed Web of Science ®Google Scholar
• Lehle K, Birnbaum DE, Preuner JG. Predominant inhibition of interleukin-6 synthesis in patient-specific endothelial cells by mTOR inhibitors below a concentration range where cell proliferation is affected and mitotic arrest takes place. Transplant Proc. 2005;37:159–161.
   PubMedGoogle Scholar
• Puglisi RN, Strande L, Santos M, Beneficial effects of cyclosporine and rapamycin in small bowel ischemic injury. J Surg Res. 1996;65:115–118.
   PubMed Web of Science ®Google Scholar
• Reis F, Parada B, Teixeira de Lemos E, Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant Proc. 2009;41:868–873.
   PubMed Web of Science ®Google Scholar
• Crowe A, Bruelisauer A, Duerr L, Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats. Drug Metab Dispos. 1999;27:627–632.
   PubMed Web of Science ®Google Scholar
• Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Paharmacokinet. 2004;43:83–95.
   PubMed Web of Science ®Google Scholar
• Okhawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351–358.
   PubMed Web of Science ®Google Scholar
• Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497–500.
   PubMed Web of Science ®Google Scholar
• Lopez-Neblina F, Toledo-Pereyra LH, Mirmiran R, Time dependence of Na-nitroprusside administration in the prevention of neutrophil infiltration in the rat ischemic kidney. Transplantation. 1996;61:179–183.
   PubMed Web of Science ®Google Scholar
• Sahna E, Parlakpinar H, Ozturk F, The protective effects of physiological and pharmacological concentrations of melatonin on renal ischemia-reperfusion injury in rats. Urol Res. 2003;31:188–193.
   PubMedGoogle Scholar
• Adkins JR, Silendirresena MR, Wang Z, Rapamycin inhibits release of tumor necrosis factor-α from human vascular smooth muscle cells. Am Surg. 2004;70:384–387.
   PubMedGoogle Scholar
• Donahoo KK, Shames BD, Harken AH, The role of tumor necrosis factor in renal ischemia-reperfusion injury. J Urol. 1999;162:196–203.
   PubMedGoogle Scholar
• Meldrum KK, Meldrum DR, Hile KL. p38MAPK mediates renal tubular cell TNF-α production and TNF-α dependent apoptosis during simulated ischemia. Am J Physiol Cell Physiol. 2001;281:563–570.
   PubMed Web of Science ®Google Scholar
• Donnahoo KK, Meldrum DR, Shenkar R, Early renal ischemia, with or without reperfusion, activates NFkB and increases TNF-α bioactivity in the kidney. J Urol. 2000;163:1328–1332.
   PubMed Web of Science ®Google Scholar
• Donnahoo KK, Meng X, Ao L, Differential cellular immunolocalization of renal tumor necrosis factor-α production during ischemia versus endotxaemia. Immunology. 2001;102:53–58.
   PubMedGoogle Scholar
• Patel NSA, Chatterjee PK, Di Paola R. Endogenous interleukin-6 enhances the renal injury, dysfunction, and inflammation caused by ischemia/reperfusion. J Pharmacol Exper Ther. 2005;312:1170–1178.
   PubMed Web of Science ®Google Scholar
• Yokota N, O'Donnell M, Daniels F. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2003;23:13–17.
   PubMed Web of Science ®Google Scholar
• Baud L, Ardaillou R. Involvement of reactive oxygen species in kidney damage. Br Med Bull. 1993;49:621–629.
   PubMed Web of Science ®Google Scholar
• Greene EL, Paller MS. Oxygen free radicals in acute renal failure. Miner Electrolyte Metab. 1991;17:124–132.
   PubMedGoogle Scholar
• Dobashi K, Ghosh B, Orak JK, Kidney ischemia-reperfusion: Modulation of antioxidant defenses. Mol Cell Biochem. 2000;205:1–11.
   PubMed Web of Science ®Google Scholar
• Ysebaert DK, De Greef KE, Vercauteren SR. Identification and kinetics of leukocytes after severe ischaemia/reperfusion renal injury. Nephrol Dial Transplant. 2000;15:1562–1574.
   PubMed Web of Science ®Google Scholar
• Daniel C, Renders L, Amann K, Mechanisms of everolimus-induced glomerulosclerosis after glomerular injury in the rat. Am J Transplant. 2005;5:2849–2861.
   PubMed Web of Science ®Google Scholar
• Goncalves GM, Cenedeze MA, Feitoza CQ. The role of heme oxygenase 1 in rapamycin-induced renal dysfunction after ischemia and reperfusion injury. Kidney Int. 2006;70:1742–1749.
   PubMed Web of Science ®Google Scholar
• Lieberthal W, Fuhro R, Andry CC. Rapamycin impairs recovery from acute renal failure: Role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol. 2001;281:693–706.
   PubMed Web of Science ®Google Scholar